Table 2.
Primary and secondary efficacy outcomes: within-subjects change in apnea hypopnea indices with dronabinol.
| Parameter | Baseline to 3 weeks (n = 15) Mean (SD) | 95% CI |
|---|---|---|
| ΔAHI | −14.11 (17.56) | −23.8, −4.4 |
| REM ΔAHI | −5.31 (20.84) | −16.8, 6.2 |
| NREM ΔAHI | −16.31 (18.03) | −26.3, −6.3 |
| Supine ΔAHI | −15.23 (23.03) | −28.5, −1.9 |
| Non-Supine ΔAHI | −9.84 (16.58) | −19.8, 0.2 |
| ΔAHI 1st Half | −14.70 (23.79) | −27.9, −1.5 |
| ΔAHI 2nd Half | −14.92 (18.31) | −25.0, −4.8 |
ΔAHI, change in apnea hypopnea index at week 3 of dronabinol treatment compared to baseline; REM, rapid eye movement sleep; NREM, non-rapid eye movement sleep, 1st and 2nd Half, first and second 4 h of polysomnography recording time; 95% CI, Confidence Interval for paired t-tests.
Bold entries signify statistically significant changes.